ReviewArthritis research & therapy2017
Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?
Review in Arthritis research & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Molecular profiling of rheumatoid arthritis patients reveals an association between innate and adaptive cell populations and response to anti-tumor necrosis factor.Arthritis research & therapy · 2019Trial
- A Combined Serum Biomarker Panel for Early Prediction of Response to Anti-TNF Therapy in Rheumatoid Arthritis: Toward a Precision Medicine Approach.Diagnostics (Basel, Switzerland) · 2026Article
- Identifying Predictive Biomarkers of Response in Patients With Rheumatoid Arthritis Treated With Adalimumab Using Machine Learning Analysis of Whole-Blood Transcriptomics Data.Arthritis & rheumatology (Hoboken, N.J.) · 2025Article
- Programmable chronogenetic gene circuits for self-regulated circadian delivery of biologic drugs.Journal of controlled release : official journal of the Controlled Release Society · 2025Article
- High-Titer Rheumatoid Factor is Associated with Worse Clinical Outcomes and Higher Needs for Advanced Therapies in Rheumatoid Arthritis Under Real-Life Conditions.Rheumatology and therapy · 2025Article
- Real-World Sarilumab Use and Rule Testing to Predict Treatment Response in Patients with Rheumatoid Arthritis: Findings from the RISE Registry.Rheumatology and therapy · 2023Article
- Is Tofacitinib Effectiveness in Patients with Rheumatoid Arthritis Better After Conventional Than After Biological Therapy? - A Cohort Study in a Colombian Population.Biologics : targets & therapy · 2022Article
- Expectations and educational needs of rheumatologists, rheumatology fellows and patients in the field of precision medicine in Canada, a quantitative cross-sectional and descriptive study.BMC rheumatology · 2021Article
- Multi-omics approach to precision medicine for immune-mediated diseases.Inflammation and regeneration · 2021Review
- Accessibility to biologics and its impact on disease activity and quality of life in patients with rheumatoid arthritis in Kuwait.Clinical rheumatology · 2021Article
- Berberine Delays Onset of Collagen-Induced Arthritis through T Cell Suppression.International journal of molecular sciences · 2021Article
- Nutrition and Rheumatoid Arthritis in the 'Omics' Era.Nutrients · 2021Review
- Factors Determining Retreatment Time Interval of Rituximab in Korean Patients With Rheumatoid Arthritis.Frontiers in medicine · 2021Article
- Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study.Arthritis research & therapy · 2020Article
- Platelet Rich Plasma for Treatment of Rheumatoid Arthritis: Case Series and Review of Literature.Case reports in rheumatology · 2020Article
- JAK Inhibitors and Modulation of B Cell Immune Responses in Rheumatoid Arthritis.Frontiers in medicine · 2020Review
- Expression of STAT3-regulated genes in circulating CD4+ T cells discriminates rheumatoid arthritis independently of clinical parameters in early arthritis.Rheumatology (Oxford, England) · 2019Article
- Major Challenges in Rheumatology: Will We Ever Treat Smarter, Instead of Just Harder?Frontiers in medicine · 2019Article
- Clinical Applications of Synovial Biopsy.Frontiers in medicine · 2019Review
- The Clinical Value of Autoantibodies in Rheumatoid Arthritis.Frontiers in medicine · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Individualising biologic disease-modifying anti-rheumatic drugs (bDMARDs) to maximise outcomes and deliver safe and cost-effective care is a key goal in the management of rheumatoid arthritis (RA). Investigation to identify predictive tools of bDMARD response is a highly active and prolific area of research. In addition to clinical phenotyping, cellular and molecular characterisation of synovial tissue and blood in patients with RA, using different technologies, can facilitate predictive testing. This narrative review will summarise the literature for the available bDMARD classes and focus on where progress has been made. We will also look ahead and consider the increasing use of 'omics' technologies, the potential they hold as well as the challenges, and what is needed in the future to fully realise our ambition of personalised bDMARD treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.